This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Laboratories Nexelis Canada, Inc, located at 525 Boul Cartier O Laval, Qc H7V 3S8 Canada for the sequencing of custom purified CDNA’s and proteins.
The Laboratory of Infectious Diseases (LID) within the National Institute of Allergy and Infectious Diseases (NIAID) focuses on viral vaccine development, host immune response to viruses, and viral molecular biology and genetics. Major long-term programs are dedicated to understanding and preventing viral hepatitis, severe childhood respiratory diseases, and viral gastroenteritis. Newer programs focus on developing vaccines for pandemic influenza, West Nile virus, human metapneumovirus, and SARS-CoV—from basic research to clinical trials.
The laboratory (the structural informatics unit) designs and studies the structure and epitopes display of influenza hemagglutinin antigens formulated into different mixtures of adjuvants to study influenza vaccines in terms of immunogenicity, biochemical and electron microscopic techniques. As such the purified codon-optimized cDNAs and hemagglutinin proteins will be used to carry out vaccine. Because high expression levels are needed the codon optimized cDNAs sequencing is needed to make hemagglutinin proteins for experimental studies. cDNAs and proteins from the vendor have been used by others in the field and have proven to be of sole unique high quality and allowed successful experiments and met the requirement of concentrated, purified, characterized cDNA and proteins for biochemical and animal studies.
The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered. The documents must be submitted via the NIAID electronic Simplified Acquisition Submission System (eSASS) website at https://esass.nih.gov, (subject line to reference NOI-NIAID-24-2226825 by 12:00 pm eastern standard time September 6, 2024. All vendors must register in the eSASS system to submit a quotation. Instructions on how to register / submit quotes are included on the website. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All responsible sources may submit an offer that will be considered by this Agency.
